Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 91

Results For "CENT"

4439 News Found

Replacing confusion with clarity: Global Cancer Care launches Mumbai ops to tackle detection delays
News | December 21, 2025

Replacing confusion with clarity: Global Cancer Care launches Mumbai ops to tackle detection delays

The initiative is focused on a problem that continues to plague cancer outcomes in India


Gut health crisis fuelling anxiety, early ageing & lifestyle diseases
Healthcare | December 21, 2025

Gut health crisis fuelling anxiety, early ageing & lifestyle diseases

The seminar aimed to raise public awareness about inflammageing—chronic, low-grade inflammation that silently damages the body and accelerates ageing


Takeda posts strong Phase 3 win for oral psoriasis drug
Clinical Trials | December 21, 2025

Takeda posts strong Phase 3 win for oral psoriasis drug

Takeda said zasocitinib was generally well tolerated, with a safety profile consistent with earlier studies


Soligenix publishes promising Phase 2a data for SGX945 in Behcet's Disease
Clinical Trials | December 21, 2025

Soligenix publishes promising Phase 2a data for SGX945 in Behcet's Disease

SGX945 delivered beneficial effects in 7 of 8 patients suffering from painful oral ulcers


SandboxAQ, MapLight team up to target novel CNS therapy with AI-driven drug discovery
R&D | December 20, 2025

SandboxAQ, MapLight team up to target novel CNS therapy with AI-driven drug discovery

SandboxAQ will receive an upfront payment and could earn up to $200 million in milestone payments tied to preclinical, development, regulatory, and commercial achievements


Fortis invests  Rs. 840 crore for 300+ beds in Bengaluru
Hospitals | December 20, 2025

Fortis invests Rs. 840 crore for 300+ beds in Bengaluru

Company acquires People Tree Hospital Yeshwanthpur for Rs. 430 crore


Gilead’s new HIV therapy shows promising Phase 3 results
Clinical Trials | December 19, 2025

Gilead’s new HIV therapy shows promising Phase 3 results

The study found BIC/LEN to be statistically non-inferior to BIKTARVY, Gilead’s current standard-of-care therapy


Takeda joins BaseLaunch to boost early-stage biotech ventures in Europe
News | December 19, 2025

Takeda joins BaseLaunch to boost early-stage biotech ventures in Europe

BaseLaunch has supported 27 biotech companies across multiple modalities and indications


Ambros Therapeutics launches with $125 million to advance breakthrough therapy for rare pain disorder
News | December 19, 2025

Ambros Therapeutics launches with $125 million to advance breakthrough therapy for rare pain disorder

The funding will support the pivotal Phase 3 clinical trial of neridronate in CRPS-1